VCR chemotherapy, HDAC inhibition, and SMARCA4 inhibition

The chemotherapy agent VCR sulfate, used here in the treatment of Rh30 and U23674 cells, was obtained from Sigma (product no. V8879). HDACis used in this study were purchased from Selleckchem: ENT (also known as MS-275, a class I HDACi; catalog no. S1053), PAN (a broad-spectrum HDACi; catalog no. S1030), SAHA (catalog no. S1047), CUDC-907 (a PI3K inhibitor and a class I and class II HDACi; catalog no. S2759), and CUDC-101 (a class I and class II HDACi and an inhibitor of epidermal growth factor receptor family members EGFR and HER2; catalog no. S1194). aRMS cell lines and primary tumor cell cultures were treated with these drugs at their clinically relevant C_max (maximum plasma concentrations) or, where C_max is not yet reported, their determined IC₂₅.